AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02884765 — intervention group
Intervention type: PROCEDURE
Intervention: Non-surgical / Surgical
Description: Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture
Study NCT02884765 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical
Description: Surgical treatment in both condylar fractures
Study NCT01174238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
Study NCT01174238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
Study NCT01174238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
Study NCT00898443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidural anesthetic
Description: Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
Study NCT00898443 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spinal anesthetic
Description: This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
Study NCT04574479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supra-inguinal fascia iliaca compartment block
Description: Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.~Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
Study NCT04574479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia and PCA morphine pump
Description: Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
Study NCT04574479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal analgesia and PCA morphine pump
Description: Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
Study NCT03142971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: focused shock wave therapy
Study NCT03142971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound therapy
Study NCT01369901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A functional exercise program
Study NCT01369901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A stretching exercise program
Study NCT03975023 — intervention group
Intervention type: DEVICE
Intervention: NeuroCatch Platform (NCP)
Description: The NCP plays a proprietary 6-minute auditory stimulus sequence of tones and words that elicit involuntary evoked responses in the brain. Tone stimuli elicit N100 and P300 responses, and spoken word pairs elicit N400 responses. The NCP proprietary software identifies the latency and amplitude (timing and size) of three selected ERPs. Latency and amplitude values are reported as empirical (measured) values.
Study NCT00724295 — intervention group
Intervention type: DRUG
Intervention: peginterferon alfa-2b
Description: PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
Study NCT00724295 — intervention group
Intervention type: DRUG
Intervention: ribavirin
Description: Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
Study NCT01868451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (SGN-35)
Study NCT01868451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCL
Study NCT01868451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Study NCT01868451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study NCT01868451 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-Site Radiation Therapy (ISRT)
Study NCT01868451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interim PET
Study NCT01868451 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: consolidation volume RT (CVRT)
Study NCT05138913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA
Description: After the arthroscopic operation was completed, a local TXA injection was performed
Study NCT05138913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After the arthroscopic operation was completed, a local saline injection was performed
Study NCT03706950 — intervention group
Intervention type: DRUG
Intervention: Elpida® + 2 NRTIs
Description: Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
Study NCT01050205 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current Intervention
Description: Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings.
Study NCT01050205 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention
Description: Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings.
Study NCT01238289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Education
Description: Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
Study NCT01238289 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group continues with standard care at the community health center
Study NCT04097522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
Study NCT04097522 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback
Description: During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
Study NCT00324701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepsychology
Description: therapy done at patients house
Study NCT00324701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face therapy
Description: therapy delivered at the VAMC
Study NCT01561222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 0.25 ug per day for one year
Study NCT01561222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one pill per day
Study NCT03093779 — intervention group
Intervention type: OTHER
Intervention: Health Information Assessment
Description: Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
Study NCT01119001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P300 Brain Computer Interface Keyboard
Description: Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
Study NCT01891721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness Program (BFP)
Description: This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session.
Study NCT01891721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Package (Cogpack)
Description: This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises.
Study NCT01891721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Computer Games (Sporcle)
Description: Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours.
Study NCT02827136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch and hypafix
Description: Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction
Study NCT02827136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hypafix
Description: Appliance of hypafix on both shoulder tip after anesthetic induction
Study NCT02721823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle-modification
Description: The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
Study NCT02721823 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
Study NCT00584883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT 510
Description: ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
Study NCT02684279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 4, 6, 8 mg flexibly dosed once daily
Study NCT04014361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154885 - Capsule
Description: Administered orally.
Study NCT04014361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Administered orally.
Study NCT04014361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.
Study NCT04014361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Administered orally.
Study NCT04014361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154885 - Tablet
Description: Administered orally.
Study NCT02338349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Study NCT02593786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02620267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS Stimulation
Description: Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
Study NCT02789735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active laser therapy
Description: Laser therapy at predetermined sites
Study NCT02789735 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser therapy
Description: Sham therapy at predetermined sites
Study NCT04534504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SG-JJB
Description: Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
Study NCT04534504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SG-JJB
Description: Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
Study NCT03193788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle
Study NCT03193788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
Study NCT03193788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 Injection
Description: vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment
Study NCT03193788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions
Study NCT02823808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NESINA ACT TAB. 25/15mg
Description: Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
Study NCT02823808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMARYL-M TAB. 2/500mg
Description: Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
Study NCT01019980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Description: Diclofenac potassium
Study NCT01019980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen
Study NCT01152762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized Respiratory Physiotherapy
Description: Standardized Respiratory Physiotherapy during 6 months
Study NCT03947125 — intervention group
Intervention type: DRUG
Intervention: Buprenorphine transdermal patch on knee joint
Description: Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.
Study NCT01608542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100mg
Description: oral tablet
Study NCT01608542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib 200mg
Description: oral tablet
Study NCT01301651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balance training
Description: 30 minute each time, 2 times per week for 6 weeks.
Study NCT02885805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987516
Description: 2.00 mg/cm2 ± 0.04 mg/cm2
Study NCT02885805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: 2.00 mg/cm2 ± 0.04 mg/cm2
Study NCT06352047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The effect of positioning on respiratory functions of preterm infants after extubation.
Description: Position changes and the direction of the position (supine, prone, side lying) are recorded in the nurse observation form.
Study NCT06352047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of positioning on respiratory functions of preterm infants after extubation.
Description: Position changes and the direction of the position (supine, prone, side lying) are recorded in the nurse observation form.
Study NCT01979835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GyneFix Viz
Description: insertion of GyneFix Viz and measurment of the SA distance
Study NCT04038853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1,25-Dihydroxyvitamin D
Description: 1,25-dihydroxy-vitamin D3 1000 IU orally daily for 12 months
Study NCT04038853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to the study intervention drug
Study NCT00671554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melaxin (autologous dendritoma vaccine) and BCG
Description: Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
Study NCT04272970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Validation of a new gene / protein variant implicated in familial CT
Description: Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
Study NCT04272970 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Validation of a new gene / protein variant implicated in familial CT
Description: Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
Study NCT01479829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)
Study NCT01479829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)
Study NCT01479829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib is a nonsteroidal anti-inflammatory drug
Study NCT01479829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a manufactured capsule with no active ingredient
Study NCT00601250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: linagliptin
Description: Patients receive linagliptin 5 mg tablets once daily